Neuroscience

Halcon Marketing Solutions Launches New Service Offerings Amidst a Post-Pandemic Economic Boon

Retrieved on: 
Tuesday, April 2, 2024
MTV, Certification, COVID, Social media, DNA, Neuroscience, Psychology, Marketing, Fox Entertainment Group, Cognitive science, Paramount Network, Asset management

St. Louis, Missouri--(Newsfile Corp. - April 2, 2024) - HALCON Marketing Solutions , founded by Nicole Powell , has achieved certification in Neuromarketing, an innovative discipline merging neuroscience and cognitive science with marketing strategies.

Key Points: 
  • St. Louis, Missouri--(Newsfile Corp. - April 2, 2024) - HALCON Marketing Solutions , founded by Nicole Powell , has achieved certification in Neuromarketing, an innovative discipline merging neuroscience and cognitive science with marketing strategies.
  • This certification allows the company to unveil new services tailored to navigating the complexities of post-COVID sales.
  • This comprehensive approach empowers clients to develop finely tuned marketing strategies that effectively adapt to consumers' evolving preferences.
  • In addition, HALCON provides a suite of marketing services that span brand strategy, social media management, email marketing, design, content creation, web development, and strategic branding.

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

Retrieved on: 
Tuesday, April 9, 2024
Toxicity, PMN, MSA, Bioorganic chemistry, ALS, Multiple system atrophy, Zebrafish, SOD1, Neuroscience, Journal, Brain cell, TAR, Protein, Biochemistry, PROMIS, Antibody, Therapy, Vaccine

ProMIS is developing antibodies selectively targeting misfolded forms of TDP-43 and SOD1.

Key Points: 
  • ProMIS is developing antibodies selectively targeting misfolded forms of TDP-43 and SOD1.
  • ALS is a fatal neurodegenerative disease of motor neurons.
  • “Publication of these data underscores the connection of misfolded proteins and ALS and supports targeting our TDP-43-specific epitope with PMN267 as a potential therapeutic approach,” stated Neil Warma, Chief Executive Officer of ProMIS Neurosciences.
  • “PMN267 is advancing through preclinical development and is showing promise as a potential treatment for ALS.

Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference

Retrieved on: 
Wednesday, April 3, 2024
Conference, Depression, ADAA, Patient, Anxiety, Neuroscience, Poster, Postpartum depression

The presentations will highlight the Phase 1 findings on RE104, a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT, a psilocybin-like compound.

Key Points: 
  • The presentations will highlight the Phase 1 findings on RE104, a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT, a psilocybin-like compound.
  • In a Phase 1 study, RE104 produced a psychedelic, psychoactive state similar in intensity and quality to psilocybin, but lasting only about half the time (3-4 hours) while demonstrating a similar, favorable safety profile.
  • Reunion is evaluating RE104 in patients with underserved mental health disorders, beginning with postpartum depression ( NCT06342310 ).
  • Details of the presentations are as follows:
    Location: Westin Boston Seaport District: Harbor Ballroom I & II, Harbor Level
    The poster will be available on Reunion’s website on Friday, April 12, 2024.

Enhancing Positive Emotions to Prevent Depression in Youth - A Free Webinar from the Brain & Behavior Research Foundation

Retrieved on: 
Tuesday, April 2, 2024
Depression, Emotion, Vanderbilt University, Mood, Associate, Risk, Research, Neuroscience, Brain, Psychology, Happiness, CDC, Suicide, Sadness

The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Enhancing Positive Emotions to Prevent Depression in Youth” on Tuesday, April 9, 2024, at 2:00 pm ET, offering new insights on addressing depression in children and young adults.

Key Points: 
  • The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Enhancing Positive Emotions to Prevent Depression in Youth” on Tuesday, April 9, 2024, at 2:00 pm ET, offering new insights on addressing depression in children and young adults.
  • Jeffrey Borenstein, M.D., President & CEO of the Brain & Behavior Research Foundation, and host of the public television series Healthy Minds will be the webinar host.
  • Register today at BBRFoundation.org
    Treatment for depression traditionally focuses on reducing negative emotions like sadness or anger and less on increasing positive emotions like contentment and happiness.
  • In this talk, Dr. Kujawa will first review research informed by neuroscience that highlights difficulties with positive emotions as a key risk factor for the development of depression in youth.

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Retrieved on: 
Monday, April 1, 2024
Research, PMN, FTLD, Biotechnology, MSA, ALS, Multiple system atrophy, CSF, Patient, Neuroscience, Epitope, Immunoglobulin G, RACK1, Cerebrospinal fluid, Activated, Synucleinopathy, Clinical trial, PROMIS, Antibody, Vaccination, Safety, Pharmacokinetics, Interim, Therapy, Blood, SAD, Frontotemporal lobar degeneration, Pharmaceutical industry

This is a very exciting opportunity for both ProMIS and the AD patients we aim to serve.

Key Points: 
  • This is a very exciting opportunity for both ProMIS and the AD patients we aim to serve.
  • ProMIS dosed the first participants in a first-in-human Phase 1a clinical trial of PMN310 as a potential treatment for AD in November 2023 (Study NCT06105528 ).
  • Using a proprietary computational platform, ProMIS identified potential conformational epitopes (misfolded portions) unique to toxic alpha-synuclein involved in synucleinopathies.
  • Cash and cash equivalents were $12.6 million as of December 31, 2023, compared to $5.9 million as of December 31, 2022.

Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy

Retrieved on: 
Thursday, March 28, 2024
Synthetic media, Neuroscience, Growth, Urology, Partnership, Knowledge, Acquisition, Health Canada, Immunology, Investment, Safety, PMDA, Trilogy, Endocrinology, Generative

PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies.

Key Points: 
  • PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies.
  • The acquisition by Indegene Ireland, a subsidiary of Indegene Limited, augments Indegene’s depth of clinical and regulatory writing expertise for market authorization applications globally.
  • Trilogy Writing & Consulting is a Germany, UK, and US-based, medical writing consultancy with know-how in the development and delivery of clinical, regulatory, safety, and medical content.
  • It applies its expertise and unique approaches to deliver quality medical writing output.

Indegene acquires Trilogy Writing & Consulting GmbH, a medical writing consultancy

Retrieved on: 
Wednesday, March 27, 2024
Seyfarth Shaw, Synthetic media, Neuroscience, Growth, Urology, Partnership, Knowledge, Acquisition, Health Canada, Immunology, Investment, Safety, PMDA, Trilogy, Endocrinology, Generative

PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies.

Key Points: 
  • PRINCETON, N.J. and FRANKFURT, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization company, announced the acquisition of Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities across clinical, regulatory, safety and medical content to life sciences companies.
  • The acquisition by Indegene Ireland, a subsidiary of Indegene Limited, augments Indegene’s depth of clinical and regulatory writing expertise for market authorization applications globally.
  • Trilogy Writing & Consulting is a Germany, UK, and US-based, medical writing consultancy with know-how in the development and delivery of clinical, regulatory, safety, and medical content.
  • It applies its expertise and unique approaches to deliver quality medical writing output.

Tetricus Labs Partners with Silver Hill Hospital on Research to Advance Precision Psychiatry

Retrieved on: 
Tuesday, April 9, 2024
Data Management, Technology, Other Health, Health, Neurology, Mental Health, Research, Software, Artificial Intelligence, Hospitals, Science, Dow, Panic disorder, Psychiatry, Data science, Associate, Silver, Partnership, Patient, Tetricus, Bipolar disorder, Radiology, Neuroscience, Doctor of Philosophy, DSM-IV codes, Evercore, MD, Psychology, Silver Hill Hospital, Social anxiety disorder, Machine learning, Medical director, Yale University, Medicine, Nursing

Precision psychiatry startup Tetricus Labs has partnered with Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, on a two-year feasibility study to assess how machine learning can significantly improve patient outcomes.

Key Points: 
  • Precision psychiatry startup Tetricus Labs has partnered with Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, on a two-year feasibility study to assess how machine learning can significantly improve patient outcomes.
  • “We're patient-founded, patient-owned, and patient-run,” said Dow, CEO for Tetricus Labs.
  • Andrew J. Gerber, MD, PhD, President and Medical Director of Silver Hill Hospital, will join Tetricus Labs as a Medical Advisor to ensure Tetricus’ machine learning software is designed to fit within the busy workflow of hospital clinicians and staff, maximizing its accessibility for providers and potential impact on patient outcomes.
  • “This partnership represents our continued commitment to exploring innovative methods that can enhance our understanding of psychiatric disorders and improve patient outcomes."

Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors

Retrieved on: 
Tuesday, April 9, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Neuroscience, Juno Therapeutics, Genentech, Cornell University, Heredity, Patient, Carmustine, Acquisition, Allergy, Senior, Research and development, Therapy, Drug development, Rituximab, Management

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors.

Key Points: 
  • Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced the appointment of Sunil Agarwal, M.D., to its Board of Directors.
  • Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience.
  • “It is a pleasure to welcome Sunil to our Board of Directors,” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics.
  • “STAR-0215 has the potential to significantly improve the lives of patients and I look forward to contributing to its progress at this exciting time.”
    Dr. Agarwal currently serves on the Board of Directors of Arvinas and was previously a Board member of Calithera Biosciences, MyoKardia, and Vitrisa Therapeutics.

Tampa General Hospital Honored as a Leading Industry Innovator by Modern Healthcare

Retrieved on: 
Tuesday, April 9, 2024
Research, Tampa General Hospital, Culture, Sepsis, Organization, Biotechnology, Growth, Rehabilitation hospital, Environment, Intelligence, Partnership, Education, TGH, Patient, News, Neuroscience, Student, GE HealthCare, City, Investment, Infection, Patient safety, Modern Healthcare, Workplace, Surgery, Nursing

TAMPA, Fla., April 9, 2024 /PRNewswire/ -- Tampa General Hospital (TGH) is one of 10 organizations nationwide recognized in Modern Healthcare's Innovators Class of 2024. This award program highlights leaders and organizations, selected by Modern Healthcare's editorial team, who are driving innovation that improves care, achieves measurable results and advances the clinical and financial goals of the organization.

Key Points: 
  • TAMPA, Fla., April 9, 2024 /PRNewswire/ -- Tampa General Hospital (TGH) is one of 10 organizations nationwide recognized in Modern Healthcare's Innovators Class of 2024.
  • "At Tampa General, we're dedicated to driving innovation by leveraging the latest technologies, forging dynamic partnerships and implementing strategic initiatives that enhance patient outcomes, accessibility and affordability," said John Couris, president and CEO of Tampa General.
  • Modern Healthcare is a leading source of healthcare business news.
  • Tampa General and the full Innovators Class of 2024 are profiled in the April 8 print edition of the magazine and online here .